A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.

Anjali S AdvaniBrenda CooperValeria ViscontePaul ElsonRicky ChanJennifer CarewWei WeiSudipto MukherjeeAaron GerdsHetty E CarrawayAziz NazhaBetty HamiltonRonald SobecksPaolo CaimiBenjamin TomlinsonEhsan MalekJane LittleAlexander MironJohn PinkJaroslaw MaciejewskiAllison UngerMatt KalaycioMarcos de LimaMikkael A Sekeres

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

These results are encouraging, but a randomized trial is needed to address whether the addition of ixazomib to MEC improves outcome. Gene-expression profiling also helped us identify predictors of response and potentially novel therapeutic targets.

Keyphrases

acute myeloid leukemia
genome wide
genome wide identification
allogeneic hematopoietic stem cell transplantation
phase iii
study protocol
clinical trial
copy number
phase ii
dna methylation
transcription factor
gene expression
open label
multiple myeloma
low dose
double blind